Skip to main content
Clinical Trials/CTRI/2016/11/007511
CTRI/2016/11/007511
Recruiting
Phase 4

Assessment of Efficacy, Tolerability and Safety of Steroneo Skin Cream (Physalis Angulata Supercritical Extract) application for treatment of eczematous lesions: A Prospective, Open-label, Non-Comparative Study

Rehmat Clinic0 sites50 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Rehmat Clinic
Enrollment
50
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Sponsor
Rehmat Clinic

Eligibility Criteria

Inclusion Criteria

  • Clinically diagnosed with eczematous lesions of any of the following types and requiring mild to moderate topical steroid therapy:
  • Atopic dermatitis
  • Contact dermatitis
  • Xerotic eczema
  • Nodular eczema
  • Seborrheic dermatitis
  • Neurocutaneous dermatitis (lichen simplex chronicus)
  • Drug eruptions, photo\-dermatitis
  • Pruritus requiring topical corticosteroids
  • Patients/parents who sign the written informed consent form

Exclusion Criteria

  • 1\.Patients having any of the following conditions:
  • Lichen planus
  • Severe dermatitis requiring systemic corticosteroids
  • Infantile dermatitis
  • 2\.Patients requiring systemic corticosteroids on any form
  • 3\.Pregnant and lactating women
  • 4\.Patients with known hypersensitivity to any of the ingredients/excipients of the study cream
  • 5\.Any other condition, which in the opinion of the clinician/investigator, could interfere significantly with the treatment and assessment process
  • 6\.Use of any investigational therapy within 30 days prior to randomization
  • 7\.Patients not willing to provide written informed consent

Outcomes

Primary Outcomes

Not specified

Similar Trials